SWISF - New to The Street Announces Episode 530 with Six Corporate Interviews Airing on the Fox Business Network Monday November 20 2023 at 10:30 PM PT | Benzinga
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the 530th episode lineup of its national business TV show, airing on Monday, November 20, 2023, at 10:30 PM PT on the Fox Business Network. The show features a new business segment, "The Business of Blockchain," with TV Host Jane King.
New to The Street airs the following six (6) corporate interviews:
1). Biopharmaceutical – Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) () interview with David Luci, President/CEO.
2). Plastic Waste Conversion- Clean Vision Corp.'s (OTCQB:CLNV) () interview with Dan Bates, CEO.
3). Fintech – AppTech Payments Corp.'s (NASDAQ:APCX) (NASDAQ:APCXW) () ("AppTech") interview with Luke D'Angelo, CEO/Chairman.
4). Precision Mapping Solutions – ProStar Holdings, Inc.'s (OTCQX:MAPPF) (TSXV:MAPS) (FSE: 5D00) () interview with Page Tucker, Chief Executive Officer.
5). New Blockchain Segment - "The Business of Blockchain," with TV Host Jane King; Microlending on the Blockchain" topic sponsored by Verda Ventures; interviews with Jia's Zack Mark, CEO/Co-Founder, Huma Finance's ("Huma") Jaou Toure, Head of Business & Operations, and Verda Ventures' Alex Witt, General Partner.
6). "Sekur Privacy & Secure Security Segment -The Weekly Hack" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX:SWISF) (CSE:SKUR) (FRA: GDT0) (Sekur®).
Episode 530
From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Phamaceuticals, Inc. (NASDAQ:ACXP) (). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 96% success with no reinfections. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high. ACXP's Ibezapolstat study results have shown to combat no reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. David explains how the Company will fund its FDA Phase 3 study and, upon successful approval, will leverage data/results for future approval(s) with the European Medicines Agency. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching the CDI infection in hospitals and nursing homes. Acrux Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.
New to The Street's TV Host Jane King, from the Nasdaq MarketSite Studio, interviews Dan Bates, Chief Executive Officer of Clean Vision Corp. (OTCQB:CLNV) (). As a publicly traded Company, Clean Vision operates and seeks to acquire synergistic operations in the sustainable clean-technology and green energy sectors. The Company recently filed a FORM S-1 registration statement with the United Securities and Exchange Commission and awaits government approval. Along with the S-1 filing, the Company is working with NASDAQ listing officials to pursue an up-list of the Company stock to trade on the NASDAQ Exchange. Dan provides viewers with an update on its wholly-owned subsidiary Clean-Seas' operations in Quincy, West Virginia, where they are working to put a 100 tons per day (tpd) pyrolysis conversion plant into production, creating clean fuel from plastic waste. The West Virginia Department of Economic Development looks to grant the Company low-interest loans and other economic incentives to move forward with the Quincy plant. The Company's wholly-owned subsidiary, Clean-Seas, hired CDI Engineering Solutions for the Quincy plant development to provide engineering, procurement, and construction services and ERM (Environmental Resources Management) to provide environmental and permitting support for the project. The Company plans to begin processing plastic for conversion to clean energy at 100 tons per day, starting in 2024 and scaling to 500 tons per day over time. The Company has a postindustrial plastic feedstock agreement for the plant. Dan describes the conversion of feedstock into plastic oil, then sold to entities supplying recycled plastic products to large multinational organizations. Once fully operational and converting plastic waste to 500 tpd, the facility can employ about 200 people. With the West Virginia Project and other operations, the Company looks to lead the plastic recycling industry in solving plastic waste problems. The on-screen QR code is available during the show; download or visit Clean Vision Corp. - https://www.cleanvisioncorp.com/.
Luke D'Angelo, CEO /Chairman of AppTech Payments Corp. (NASDAQ:APCX) (NASDAQ:APCXW) () ("AppTech") talks with New to The Street's TV Host Jane King about corporate operations. AppTech is a leading Fintech Company specializing in and innovating seamless payment solutions for businesses and consumers. Luke explains to viewers that current economic issues, high interest rates, inflationary prices, and diminishing markets are all causing problems for companies and individuals. Bottom-line savings and increases in net profits are the objectives, and AppTech's digital payment solutions and options can assist. Merchants and their customers can save every transaction by reducing cost and time. Luke talks about the Company's recently acquired FinZeo, a software development company centered around the movement of money, nationally and globally. Management believes FinZeo will enhance the AppTech platform's current capabilities. Through the remainder of 2023 and throughout 2024, AppTech's focus is on ...